RCKT vs. BMRN

In the year-to-date period, RCKT achieves a -44.39% return, which is significantly lower than BMRN's -10.45% return. Over the past 10 years, RCKT has underperformed BMRN with an annualized return of -11.31%, while BMRN has yielded a comparatively higher -7.01% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Rocket Pharmaceuticals, Inc. (RCKT) and BioMarin Pharmaceutical Inc. (BMRN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current RCKT Sharpe Ratio is -1.03, which is comparable to the BMRN Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of RCKT and BMRN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither RCKT nor BMRN has paid dividends to shareholders.

The maximum RCKT drawdown since its inception was -94.90%, roughly equal to the maximum BMRN drawdown of -90.58%. Use the drawdown chart below to compare losses from any high point for RCKT and BMRN. For additional features, visit the drawdowns tool.

Rocket Pharmaceuticals, Inc. (RCKT) has a higher volatility of 34.55% compared to BioMarin Pharmaceutical Inc. (BMRN) at 10.67%. This indicates that RCKT's price experiences larger fluctuations and is considered to be riskier than BMRN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Rocket Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.